

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : TBA 10 580 248 Confirmation No.: TBA
Applicant : Mimi ADACHI et al.
International Filing Date : November 19, 2004
Title : METHOD FOR PROLIFERATING CARDIOMYOCYTES
TC/Art Unit : TBA
Examiner: : TBA
Docket No. : 64517.000003
Customer No. : 21967

MAIL STOP PCT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, Applicants submit the attached Form PTO-SB/08A (modified) for consideration and request the references cited therein be made of record by the U.S. Patent and Trademark Office in the above-captioned application.

Several of the references listed on the attached Form PTO-SB/08A were cited by the Japanese Patent Office in the International Search Report and the Written Opinion of the International Searching Authority for International Application No. PCT/JP2004/017274.

Applicants respectfully point out that the submission of the listed references in this Information Disclosure Statement is not an admission that they are prior art or that they are material to patentability of any claims of the application. Also, the submission of this Information Disclosure Statement is not an indication that a search has been made by Applicants.

For the convenience of the Examiner in considering the cited references, a copy of each of the cited references is enclosed with this communication. In considering the cited references, it may be noted by the Examiner that certain of the references may contain markings, underlinings, and/or other notations. These markings, underlinings, and/or other notations are not to be construed as drawing the Examiner's attention either to selected parts or away from other parts of the cited references. Any such markings were either present on the copies of the cited

references obtained by the associated individuals, or were made thereon during the study of the references by the associated individuals.


As this application was filed after June 30, 2003, copies of U.S. patents and/or U.S. patent application publications for national stage applications under 35 U.S.C. 371 cited on the attached Form PTO-SB/08A (modified), are not being provided as specified in 1276 O.G. 55 (5 August 2003).

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form SB/08B with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,
HUNTON & WILLIAMS LLP

Dated: June 5, 2006

By: 
Alexander H. Spiegler
Registration No. 56,625

Hunton & Williams LLP
Intellectual Property Department
1900 K Street, N.W.
Suite 1200
Washington, DC 20006
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)
RMS/AHS:sac

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number

TBA 10 580 248

International Filing Date

November 19, 2004

First Named Inventor

Mimi ADACHI, et al.

Art Unit

TBA

Examiner Name

Unassigned

Sheet

1 of 4

Attorney Docket Number

64517.000003

U.S. PATENT DOCUMENTS

[illegible]

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO		Application Number	TBA
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		International Filing Date	November 19, 2004
		First Named Inventor	Mimi ADACHI, et al.
		Art Unit	TBA
		Examiner Name	Unassigned
		Attorney Docket Number	64517.000003
Sheet	2 of 4		

FOREIGN PATENT DOCUMENTS

[illegible]

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	TBA
		International Filing Date	November 19, 2004
		First Named Inventor	Mimi ADACHI, et al.
		Art Unit	TBA
		Examiner Name	Unassigned
Sheet	3 of 4	Attorney Docket Number	64517.000003

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	3.	Tamamori-Adachi, et al., "Loss of skp2 Dependent Degradation of p27 Limits Cardiomyocyte Proliferative Capacity Induced by Cyclin D1NLS/CDK4," 26 th Annual Meeting of the Molecular Biology Society of Japan Program Abstract, November 25, 2003, pg.438, 01J-6.	<input type="checkbox"/>	<input type="checkbox"/>
	4.	Tamamori-Adachi, et al., "Critical Role of Cyclin D1 Nuclear Import in Cardiomyocyte Proliferation," Circulation Research, Vol. 92, No. 1, pg. 1-8, 2003.	<input type="checkbox"/>	<input type="checkbox"/>
	5.	Poolman, et al., "Altered Expression of Cell Cycle Proteins and Prolonged Duration of Cardiac Myocyte Hyperplasia in p27 ^{Kip1} Knockout Mice," Circulation Research, Vol. 85, No. 2, pg. 117-127, 1999.	<input type="checkbox"/>	<input type="checkbox"/>
	6.	Kim, et al., "Successful Inactivation of Endogenous <i>Oct-3/4</i> and <i>c-mos</i> genes in Mouse Preimplantation Embryos and Oocytes using Short Interfering RNAs," Biochemical and Biophysical Research Communications, Vol. 296, pg. 1372-1377, 2002.	<input type="checkbox"/>	<input type="checkbox"/>
	7.	Toyoshima, et al., "p27, a Novel Inhibitor of G1 Cyclin-Cdk Protein Kinase Activity, Is Related to p21," Cell, Vol. 78, No.1, pg. 67-74, July 15, 1994.	<input type="checkbox"/>	<input type="checkbox"/>
	8.	Tsvetkov, et al., "p21 ^{Kip1} Ubiquitination and Degradation is Regulated by the SCF ^{Skp2} Complex Through Phosphorylated Thr187 in p27," Current Biology, Vol. 9, No.12, pg. 661-664, 1999.	<input type="checkbox"/>	<input type="checkbox"/>
	9.	Pasumarthi, et al., "Cardiomyocyte Cell Cycle Regulation," Circulation Research, Vol. 90, pg. 1044-1054, 2002.	<input type="checkbox"/>	<input type="checkbox"/>
	10.	Kirshenbaum, et al., "Adenovirus E1A Represses Cardiac Gene Transcription and Reactivates DNA Synthesis in Ventricular Myocytes, Via Alternative Pocket Protein- and p300-binding Domains," The Journal of Biological Chemistry, Vol. 270, No. 14, pg. 7791-7794, 1995.	<input type="checkbox"/>	<input type="checkbox"/>
	11.	Kirshenbaum, et al., "Human E2F-1 Reactivates Cell Cycle Progression in Ventricular Myocytes and Represses Cardiac Gene Transcription," Developmental Biology, Vol. 179, pg. 402-411, 1996.	<input type="checkbox"/>	<input type="checkbox"/>
	12.	Soonpaa, et al., "Cyclin D1 Overexpression Promotes Cardiomyocyte DNA Synthesis and Multinucleation in Transgenic Mice," J. Clin. Invest., Vol. 99, No. 11, pg. 2644-2654, June 1997.	<input type="checkbox"/>	<input type="checkbox"/>
	13.	Toyoda, et al., " <i>jumonji</i> Downregulates Cardiac Cell Proliferation by Repressing <i>cyclin</i> D1 Expression," Developmental Cell, Vol. 5, pg. 85-97, July 2003.	<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE	DATE CONSIDERED
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	TBA
		International Filing Date	November 19, 2004
		First Named Inventor	Mimi ADACHI, et al.
		Art Unit	TBA
		Examiner Name	Unassigned
Sheet	4 of 4	Attorney Docket Number	64517.000003

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	14.	Flink, et al., "Changes in E2F Complexes Containing Retinoblastoma Protein Family Members and Increased Cyclin-dependent Kinase Inhibitor Activities During Terminal Differentiation of Cardiomyocytes," J. Mol. Cell. Cardiol., Vol. 30, pg. 563-578, 1998.	<input type="checkbox"/>	<input type="checkbox"/>
	15.	von Harsdorf, et al. "E2F-1 Overexpression in Cardiomyocytes Induces Downregulation of p21 ^{CIP1} and p27 ^{KIP1} and Release of Active Cyclin-Dependent Kinases in the Presence of Insulin-Like Growth Factor I," Circulation Research, Vol. 85, pg. 128-136, 1999.	<input type="checkbox"/>	<input type="checkbox"/>
	16.	Carrano, et al., "SKP2 is Required for Ubiquitin-mediated Degradation of the CDK Inhibitor p27," Nature Cell Biology, Vol. 1, pg. 193-199, August 1999.	<input type="checkbox"/>	<input type="checkbox"/>
	17.	Bornstein, et al., "Role of the SCF ^{Skp2} Ubiquitin Ligase in the Degradation of p21 ^{Cip1} in S Phase," The Journal of Biological Chemistry, Vol. 278, No. 28, pg. 25752-25757, July 11, 2003.	<input type="checkbox"/>	<input type="checkbox"/>
	18.	Kamura, et al., "Degradation of p57 ^{Kip2} Mediated By SCF ^{Skp2} -dependent Ubiquitylation," Proc. Natl. Acad. Sci. USA, Vol. 100, No. 18, pg. 10231-10236, September 2, 2003.	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE	DATE CONSIDERED
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.